Physician profile
Eric Kumar Singhi
NPI 1811341720
$91,138.63
in general payments reported to CMS, 2019-2025
23 companies · $61K in 2025
The $61K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $7,025 · 2024: $23K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $77K · Honoraria: $5,240 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,423 · Travel and Lodging: $3,108 · Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,841.63 |
| Honoraria | $5,240.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,423.32 |
| Travel and Lodging | $3,108.47 |
| Food and Beverage | $2,255.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $15,410.00 | 2024-2025 | Tagrisso |
| Janssen Biotech, INC. | $12,518.19 | 2024-2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $9,190.00 | 2024-2025 | |
| Novocure INC. | $9,187.77 | 2023-2025 | Optune Lua (Novottf-200t) |
| Amgen INC. | $6,848.00 | 2023-2025 | Imdelltra (Amg757) |
| Lilly USA, LLC | $5,200.00 | 2024 | Retevmo |
| Roche Diagnostics Corporation | $4,680.99 | 2025 | Ventana Pdl1 Sp142 Assay |
| Astrazeneca Pharmaceuticals Lp | $4,652.08 | 2023-2025 | Imfinzi |
| Janssen Scientific Affairs, LLC | $4,575.00 | 2024 | Rybrevant |
| Abbvie INC. | $3,882.77 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,500.00 | 2024-2025 | |
| Glaxosmithkline, LLC. | $2,900.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $2,764.56 | 2024-2025 | Libtayo |
| Janssen Global Services, LLC | $1,812.50 | 2025 | Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,740.00 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,482.75 | 2024 | Libtayo |
| Caris Mpi, INC. | $168.96 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $165.07 | 2025 | |
| Mirati Therapeutics, INC. | $151.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $124.98 | 2022 | |
| Secura Bio, INC. | $88.49 | 2022 | |
| Janssen Research & Development, LLC | $56.54 | 2022 | |
| Genentech, INC. | $38.48 | 2023 | Alecensa, Gavreto, Avastin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Singhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.